Skip to main content
Clinical Trials/JPRN-jRCT1071210120
JPRN-jRCT1071210120
Active, not recruiting
未知

An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial' - W-JHS NHL02-A

Akashi Koichi0 sites20 target enrollmentJanuary 23, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Peripheral T-cell lymphoma (including extranodal NK/T-cell lymphoma)
Sponsor
Akashi Koichi
Enrollment
20
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 23, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Akashi Koichi

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients enrolled in W\-JHS NHL02 study (jRCT2071210101\)
  • 2\) Patients providing the written informed consent.
  • 3\) Patients whose specimens for any test in 'biomarker exploration' can be submitted

Exclusion Criteria

  • Nothing particular

Outcomes

Primary Outcomes

Not specified

Similar Trials